Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): Prevalence, therapeutic innovations and stumbling blocks for clinical development.

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): Prevalence, therapeutic innovations and stumbling blocks for clinical development. Expert Opin Investig Drugs. 2020 Jan 23;: Authors: Alkhouri N PMID: 31971024 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31971024?dopt=Abstract

Source: Expert Opinion on Investigational Drugs - January 24, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research